View Older Stories View More Recent Stories

Jan 22, 2026 08:00AM CORXEL Announces $287 million Series D1 Financing to Further Advance Its Cardiometabolic Pipeline including Oral Small Molecule GLP-1 Receptor Agonist
Jan 12, 2026 07:45AM Mirador Accelerates Multi-Asset Clinical Pipeline in Immuno-Fibrotic Disease; Closes $250 Million Series B with Premier Investors
Jan 7, 2026 06:30AM Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Dec 16, 2025 08:06AM Ambros Therapeutics Launches with $125 Million Series A Financing to Advance Neridronate Through Phase 3 Registrational Program for Complex Regional Pain Syndrome Type 1
Dec 2, 2025 07:00AM Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Nov 28, 2025 09:20AM Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
Nov 19, 2025 09:08AM Pathway to Cures Invests in SeraGene Therapeutics
Nov 14, 2025 01:15PM Form 13F-NT Adage Capital Management For: Sep 30
Nov 14, 2025 01:14PM Form 13F-HR ADAGE CAPITAL PARTNERS For: Sep 30
Nov 13, 2025 04:05PM Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update
Nov 13, 2025 09:17AM Form SCHEDULE 13G iBio, Inc. Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:16AM Form SCHEDULE 13G INOVIO PHARMACEUTICALS, Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:15AM Form SCHEDULE 13G/A Sitio Royalties Corp. Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:14AM Form SCHEDULE 13G/A Dynamix Corp Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:11AM Form SCHEDULE 13G/A ABEONA THERAPEUTICS INC. Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:11AM Form SCHEDULE 13G Equillium, Inc. Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:10AM Form SCHEDULE 13G Milestone Pharmaceutical Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:09AM Form SCHEDULE 13G/A SOLENO THERAPEUTICS INC Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:08AM Form SCHEDULE 13G/A Solid Biosciences Inc. Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:07AM Form SCHEDULE 13G/A EyePoint Pharmaceuticals Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:07AM Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:06AM Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:06AM Form SCHEDULE 13G/A Centessa Pharmaceuticals Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:06AM Form SCHEDULE 13G/A Amylyx Pharmaceuticals, Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:05AM Form SCHEDULE 13G/A MeiraGTx Holdings plc Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:04AM Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:04AM Form SCHEDULE 13G OTG Acquisition Corp. I Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:04AM Form SCHEDULE 13G/A Adagio Medical Holdings, Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:03AM Form SCHEDULE 13G Talon Capital Corp. Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:03AM Form SCHEDULE 13G/A BridgeBio Oncology Thera Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:03AM Form SCHEDULE 13G Galata Acquisition Corp. Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:02AM Form SCHEDULE 13G/A ZEVRA THERAPEUTICS, INC. Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:02AM Form SCHEDULE 13G NORTHPOINTE BANCSHARES Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:01AM Form SCHEDULE 13G Highview Merger Corp. Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:01AM Form SCHEDULE 13G MONRO, INC. Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:00AM Form SCHEDULE 13G BRIGHT MINDS BIOSCIENCES Filed by: Adage Capital Management, L.P.
Nov 13, 2025 09:00AM Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Adage Capital Management, L.P.
Nov 3, 2025 04:10PM Form SCHEDULE 13G/A Praxis Precision Medicin Filed by: Adage Capital Management, L.P.
Oct 31, 2025 04:19PM Cybin completes $175 million stock offering
Oct 31, 2025 04:19PM Cybin Announces Closing of $175 Million Registered Direct Offering
Oct 31, 2025 10:42AM Form SCHEDULE 13D/A 89bio, Inc. Filed by: Adage Capital Management, L.P.
Oct 28, 2025 08:00AM Cybin raises $175 million in registered direct offering
Oct 28, 2025 08:00AM Cybin Announces $175 Million Registered Direct Offering
Oct 23, 2025 07:25AM Tango Therapeutics raises $225 million in stock offering
Oct 23, 2025 07:20AM Tango Therapeutics Announces $225 Million Financing
Oct 14, 2025 06:30AM Kailera Therapeutics Announces $600 Million Series B Financing to Further Advance Pipeline of Next-Generation Therapies for the Treatment of Obesity
Oct 3, 2025 04:01PM Form SCHEDULE 13D 89bio, Inc. Filed by: Adage Capital Management, L.P.
Oct 2, 2025 04:05PM Palisade Bio closes $138 million public offering to fund drug trial
Oct 2, 2025 04:05PM Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option
Sep 11, 2025 10:57AM UNCF Announces Dr. Shawn Thomas as Director of Investment Leadership Programs and Lead for Project ACCLAIM
View More Recent Stories View Older Stories